DNAHealthcare · BiotechnologyThe 3 Wall Street analysts covering Ginkgo Bioworks Holdings, Inc. hold a median 12-month price target of $8 — -28.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 31 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Ginkgo Bioworks Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (85): Reported profit is backed by cash, and the company is not expanding recklessly.
Volatility (16): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on DNA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −28.6% from it.
Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Oct 2026 | TD Cowen | Maintains | Hold | $9.00 → $11 |
| 4 Sept 2026 | BTIG | Reiterates | Sell | $5.00 |
| 4 Sept 2026 | BTIG | Reiterates | Sell | — |
| 7 Aug 2026 | TD Cowen | Downgrade | Hold | $12 → $9.00 |
| 7 Aug 2026 | TD Cowen | Downgrade | Hold | — |
| 12 Mar 2026 | BTIG | Maintains | Sell | $9.00 → $5.00 |
| 12 Mar 2026 | BTIG | Maintains | Sell | — |
| 8 Jan 2026 | TD Cowen | Maintains | Buy | — |
| 25 Aug 2025 | BTIG | Maintains | Sell | — |
| 20 Sept 2024 | TD Cowen | Maintains | Buy | — |
| 23 Aug 2024 | BTIG | Maintains | Sell | — |
| 9 July 2024 | Goldman Sachs | Maintains | Sell | — |
| 26 June 2024 | BTIG | Maintains | Sell | — |
| 15 May 2024 | BTIG | Downgrade | Sell | — |
| 15 May 2024 | Morgan Stanley | Maintains | Equal-Weight | — |
| 10 May 2024 | William Blair | Downgrade | Underperform | — |
| 1 Mar 2024 | TD Cowen | Maintains | Outperform | — |
| 23 Jan 2024 | Goldman Sachs | Maintains | Sell | — |
| 22 Jan 2024 | Goldman Sachs | Maintains | Sell | — |
| 15 Nov 2023 | Raymond James | Downgrade | Market Perform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
DNA appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Ginkgo Bioworks Holdings, Inc. returned −6.7% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 86% of US stocks
Cheaper than 21% of US stocks
Cheaper than 48% of US stocks
Cheaper than 77% of US stocks
Higher than 6% of US stocks
Higher than 9% of US stocks
Higher than 97% of US stocks
Higher than 9% of US stocks
Higher than 2% of US stocks
Higher than 19% of US stocks
Higher than 22% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Ginkgo Bioworks Holdings, Inc. has a market value of $754.9M and an enterprise value of $856.8M.
Revenue in the twelve months to 30 June 2026: $111.9M. The latest quarter shrank 48.5% year on year.
Net income over the same four quarters: −$290.8M, a −260.0% net margin.
Free cash flow in the twelve months to 30 June 2026: −$174.8M.
Trailing P/E: −2.0×; forward P/E: −3.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Ginkgo Bioworks Holdings, Inc. employs 485 people — $231K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Ginkgo Bioworks Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Ginkgo Bioworks Holdings, Inc. (DNA) closed at $12.74 in the latest trading session, down 4.35% from the prior day. The headline says the decline was larger than the general market.
Why it matters — The reported daily decline provides DNA watchers with an update on the stock’s recent trading performance.
Ginkgo Bioworks Holdings (DNA) closed at $9.86, down 2.09% from its previous close.
Why it matters — DNA watchers may note the stock’s decline on the latest trading day.
Ginkgo Bioworks Holdings, Inc. (DNA) closed at $11.53 in the most recent trading session, down 1.96% from the previous trading day. The headline reports that the stock fell more than the broader market.
Why it matters — DNA watchers may note the stock’s session decline and its underperformance relative to the broader market.
Ginkgo Bioworks is granting remote laboratory access through the National Science Foundation’s X-Labs program and adding high-speed cellular imaging tools to its Boston facility.
Why it matters — These steps concern Ginkgo’s biotechnology infrastructure and research capabilities, which are relevant to investors following DNA.
Ginkgo Bioworks announced it will provide in-kind access to its Boston autonomous laboratory for researchers in the National Science Foundation’s X-Labs program. The support includes cloud lab time and protein testing services for the $1.5 billion, decade-long initiative.
Why it matters — The announcement highlights Ginkgo’s contribution of laboratory access and services to a major NSF research program.
The 3 Wall Street analysts covering Ginkgo Bioworks Holdings, Inc. have a median 12-month price target of $8, with estimates ranging from $5 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Ginkgo Bioworks Holdings, Inc., 0 rate it a Buy, 1 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Ginkgo Bioworks Holdings, Inc. 43 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Ginkgo Bioworks Holdings, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (85 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies -28.6% from the last close, and Ticker Nerd's factor model ranks Ginkgo Bioworks Holdings, Inc. 43 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Ginkgo Bioworks Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DNA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $11 over the next 12 months.
Ginkgo Bioworks Holdings, Inc. returned -6.7% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Ginkgo Bioworks Holdings, Inc. Class A Common Stock represents ownership in Ginkgo Bioworks Holdings, a biotechnology company focused on cell engineering and biological design.
The most recent item we track (Zacks Investment Research, 29 Oct 2026): "Ginkgo Bioworks Holdings, Inc. (DNA) Suffers a Larger Drop Than the General Market: Key Insights". Ginkgo Bioworks Holdings, Inc. (DNA) closed at $12.74 in the latest trading session, down 4.35% from the prior day. The headline says the decline was larger than the general market.
Ginkgo Bioworks Holdings, Inc. Class A Common Stock represents ownership in Ginkgo Bioworks Holdings, a biotechnology company focused on cell engineering and biological design. Ginkgo Bioworks develops a platform that helps customers design, build, and test custom microbes and other biological systems for use in industries such as pharmaceuticals, agriculture, food, industrial chemicals, and specialty materials. The company provides biological R&D services, automation-enabled laboratory tools, and data-driven software that support the research, development, and commercialization of engineered organisms. It also serves government and commercial clients through biosecurity-related offerings that support biological monitoring and surveillance. Headquartered in Boston, Massachusetts, Ginkgo Bioworks plays a specialized role in the life sciences market by supplying infrastructure and services that make biological engineering more accessible across multiple sectors.
CEO Dr. Jason Kelly Ph.D. · 485 employees · United States · https://www.ginkgo.bio
